Efficacy and safety of transdermal buprenorphine versus transdermal fentanyl in patients with persistent postoperative pain after oral malignant tumor surgery

doi:10.19438/j.cjoms.2018.05.009

Abstract

Abstract: PURPOSE: To compare the efficacy and safety of buprenorphine transdermal patch and fentanyl transdermal patch for postoperative persistent pain after oral malignant tumor surgery. METHODS: According to a computer-generated randomized list, the patients were randomly divided into buprenorphine transdermal patch group (experimental group) and fentanyl transdermal patch group (control group), 52 cases in each group. The differences in VAS pain scores, number of remediation drug, incidence of adverse reactions, and differences in overall satisfaction between the two groups before and after use were compared on days 1, 3, 5, 7, 14, 21, and 28. SPSS 23.0 software package was used for statistical analysis. RESULTS: A total of 104 cases were included, and 96 completed the study: 49 patients in the buprenorphine transdermal patch group and 47 in the fentanyl patch group. There was no significant difference in VAS pain score between the two groups before and after the use of patch (P>0.05); there was no significant difference between the two groups in the total number of tramadol hydrochloride (P>0.05). The incidence of constipation was not statistically significant (P>0.05). The incidence of nausea, vomiting and drowsiness was significantly lower in the experimental group than in the control group (P<0.05). The patients' satisfaction of the experimental group was significantly higher than that of the control group (P<0.05). CONCLUSIONS: Transdermal buprenorphine patch for oral cancer patients with persistent pain after analgesic effect is equivalent to fentanyl patch, but with less lethargy, nausea, vomiting and fewer other adverse reactions. It is easy to use, and the degree of patients' satisfaction is high.

Key words: Buprenorphine transdermal patch, Fentanyl transdermal patch, Postoperative pain, Analgesia, Oral malignant tumor

CLC Number:

R782.05.4

LI Meng-ya, SUN Yu, JIANG Hong. Efficacy and safety of transdermal buprenorphine versus transdermal fentanyl in patients with persistent postoperative pain after oral malignant tumor surgery[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(5): 431-435.

References

[1] Chen SC, Huang BS, Chung CY, et al.Effects of a swallowing exercise education program on dysphagia-specific health-related quality of life in oral cavity cancer patients post-treatment: a randomized controlled trial[J]. Support Care Cancer, 2018, 26(8): 2919-2928.
[2] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
[3] 黄相道, 王发生, 段毅. 口腔颌面部鳞癌的手术切除及修复重建36例临床分析[J]. 当代医学, 2010, 16(3): 72-73.
[4] 郭元, 潘兴飞, 史剑杰, 等. 术后重建修复对口腔肿瘤切除患者生活质量的相关影响[J]. 中华肿瘤防治杂志, 2016, 23(s1):54-55.
[5] 孙强, 潘熊熊, 刘莉, 等. 氟比洛芬酯复合芬太尼在口腔肿瘤术后镇痛的临床研究[J]. 临床麻醉学杂志, 2013, 29(5): 467-468.
[6] Kweon S, Koo BS, Jee S.Change of swallowing in patients with head and neck cancer after concurrent chemoradiotherapy[J]. Ann Rehabil Med, 2016, 40(6): 1100-1107.
[7] Greenwald MK, Johanson CE, Moody DE, et al.Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers[J]. Neuropsychopharmacology, 2003, 28(11): 2000-2009.
[8] Mitra F, Chowdhury S, Shelley M, et al.A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain[J]. Pain Med, 2013,14(1): 75-83.
[9] Hans G, Robert D.Transdermal buprenorphine-a critical appraisal of its role in pain management[J]. J Pain Res, 2009, 2: 117-134.
[10] Lee JH, Kim JH, Kim JH, et al.Efficacy and safety of transdermal buprenorphine versus oral tramadol/acetaminophen in patients with persistent postoperative pain after spinal surgery[J]. Pain Res Manag, 2017, 2017: 2071494.
[11] Vadivelu N, Anwar M.Buprenorphine in postoperative pain management[J]. Anesthesiol Clin, 2010, 28(4): 601-609.
[12] 陈焰, 张阳春, 余世明. 丁丙诺啡透皮贴用于骨科大手术术后镇痛的效果[J]. 广东医学, 2015, 36(19): 3056-3058.
[13] Myers LL, Sumer BD, Truelson JM, et al.Impact of treatment sequence of multimodal therapy for advanced oral cavity cancer with mandible invasion[J]. Otolaryngol Head Neck Surg, 2011, 145(6): 961-966.
[14] Huxtable CA, Roberts LJ, Somogyi AA, et al.Acute pain management in opioid-tolerant patients: a growing challenge[J]. Anaesth Intensive Care, 2011, 39(5): 804-823.
[15] Martucci C, Panerai AE, Sacerdote P.Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses[J]. Pain, 2004, 110(1-2): 385-392.
[16] Filitz J, Griessinger N, Sittl R, et al.Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine[J]. Eur J Pain, 2006, 10(8): 743-748.
[17] 任晓凤, 任娜娜, 张爱文, 等. 丁丙诺啡透皮贴剂的缓释镇痛作用[J]. 中国组织工程研究, 2015, 19(21): 3339-3343.
[18] 徐建国, 王楠. 中重度疼痛治疗药丁丙诺啡透皮贴剂的药理作用及临床评价[J]. 中国新药杂志, 2013, 22(23): 2717-2720.
[19] Ruggiero A, Coccia P, Arena R, et al.Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain[J]. Pediatr Blood Cancer, 2013, 60(3): 433-437.
[20] Michel E, Anderson BJ, Zernikow B.Buprenorphine TTS for children-a review of the drug's clinical pharmacology[J]. Paediatr Anaesth, 2011, 21(3): 280-290.
[21] Plosker GL.Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain[J]. Drugs, 2011, 71(18): 2491-2509.